Aliskiren monotherapy does not cause paradoxical blood pressure rises: Meta-analysis of data from 8 clinical trials

Hypertension

Volumn 55, Issue 1, 2010, Pages 54-60

  Stanton, Alice V ^a   Gradman, Alan H ^b   Schmieder, Roland E ^c   Nussberger, Juerg ^d   Sarangapani, Ramesh ^e   Prescott, Margaret F ^e  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b WESTERN PENNSYLVANIA HOSPITAL   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Aliskiren; Angiotensin receptor blocker; Direct renin inhibitor; Diuretic; Plasma renin activity; Renin

Indexed keywords

ALISKIREN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; HUMAN; HYPERTENSION; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FUMARATES; HUMANS; HYPERTENSION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; TREATMENT OUTCOME;

EID: 73849141617     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135772     Document Type: Article

References (20)

1. Frampton JE, Curran MP. Aliskiren: A review of its use in the management of hypertension. Drugs. 2007;67:1767-1792.
2. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
3. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
4. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61: 1461-1468.
5. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007;20:587-597.
6. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens. 2009;22:112-121.
7. Sealey JE, Laragh JH. It is the plasma renin activity level that counts, not stoichiometry. Hypertension. 2008;52:e20.
8. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51:1306-1311.
9. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1151-1157.
10. Danser AHJ, Charney A, Feldman DL, Nussberger J, Fisher ND, Hol-lenberg NK. The renin rise with aliskiren: it's simply stoichiometry. Hypertension. 2008;51:e27-e28.
11. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589-599.
12. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
13. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. In press.
14. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.
15. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143.
16. Puig JG, Schunkert H, Taylor AA, Boye S, Jin J, Keefe DL. Evaluation of the dose-response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, double-blind, randomized, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 hypertension. Clin Ther. In press.
17. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihy-pertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlo-rothiazide. Circulation. 2009;119:417-425.
18. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229.
19. Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, Kler L, Brown AN, Francis RJ. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987;9:39-44. (Pubitemid 17212750)
20. Ménard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens. 2007;25: 1775-1782.